Based on these results, we conclude that rhein can be targeted to alleviate TAC operation- and AngII-induced cardiac hypertrophy by inhibiting the STAT3 and P38/MAPK signaling pathways. The gene discussed is STAT3; the disease is cardiac hypertrophy.